The DOI matches its Crossref record; 53 of the 53 references it cites were found in a registry or an index.
Medical Marketing in the United States, 1997-2016
Abstract
IMPORTANCE: Manufacturers, companies, and health care professionals and organizations use an array of promotional activities to sell and increase market share of their products and services. These activities seek to shape public and clinician beliefs about laboratory testing, the benefits and harms of prescription drugs, and some disease definitions. OBJECTIVE: To review the marketing of prescription drugs, disease awareness campaigns, health services, and laboratory tests and the related consequences and regulation in the United States over a 20-year period (1997-2016). EVIDENCE: Analysis (1997-2016) of consumer advertising (Kantar Media data for spending and number of ads); professional marketing (IQVIA Institute for Human Data Science, Open Payments Data [Centers for Medicare & Medicaid Services]); regulations and legal actions of the US Food and Drug Administration (FDA), Federal Trade Commission (FTC), state attorneys general, and US Department of Justice; and searches (1975-2018) of peer-reviewed medical literature (PubMed), business journals (Business Source Ultimate), and news media (Lexis Nexis) for articles about expenditures, content, and consequences and regulation of consumer and professional medical marketing. Spending is reported in 2016 dollars. FINDINGS: From 1997 through 2016, spending on medical marketing of drugs, disease awareness campaigns, health services, and laboratory testing increased from $17.7 to $29.9 billion. The most rapid increase was in direct-to-consumer (DTC) advertising, which increased from $2.1 billion (11.9%) of total spending in 1997 to $9.6 billion (32.0%) of total spending in 2016. DTC prescription drug advertising increased from $1.3 billion (79 000 ads) to $6 billion (4.6 million ads [including 663 000 TV commercials]), with a shift toward advertising high-cost biologics and cancer immunotherapies. Pharmaceutical companies increased DTC marketing about diseases treated by their drugs with increases in disease awareness campaigns from 44 to 401 and in spending from $177 million to $430 million. DTC advertising for health services increased from $542 million to $2.9 billion, with the largest spending increases by hospitals, dental centers, cancer centers, mental health and addiction clinics, and medical services (eg, home health). DTC spending on advertising for laboratory tests (such as genetic testing) increased from $75.4 million to $82.6 million, although the number of ads increased more substantially (from 14 100 to 255 300), reflecting an increase in less expensive electronic media advertising. Marketing to health care professionals by pharmaceutical companies accounted for most promotional spending and increased from $15.6 billion to $20.3 billion, including $5.6 billion for prescriber detailing, $13.5 billion for free samples, $979 million for direct physician payments (eg, speaking fees, meals) related to specific drugs, and $59 million for disease education. Manufacturers of FDA-approved laboratory tests paid $12.9 million to professionals in 2016. From 1997 through 2016, the number of consumer and professional drug promotional materials that companies submitted for FDA review increased from 34 182 to 97 252, while FDA violation letters for misleading drug marketing decreased from 156 to 11. Since 1997, 103 financial settlements between drug companies and federal and state governments resulted in more than $11 billion in fines for off-label or deceptive marketing practices. The FTC has acted against misleading marketing by a single for-profit cancer center. CONCLUSIONS AND RELEVANCE: Medical marketing increased substantially from 1997 through 2016, especially DTC advertising for prescription drugs and health services. Pharmaceutical marketing to health professionals accounted for most spending and remains high even with new policies to limit industry influence. Despite the increase in marketing over 20 years, regulatory oversight remains limited.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Health Care Spending in the United States and Other High-Income Countries
Papanicolas, I., Woskie, L. R., & Jha, A. K. (2018) · JAMA · doi:10.1001/jama.2018.1150 · Cited by 1,626
Physicians and the Pharmaceutical Industry: Is a Gift Ever Just a Gift?
Wazana, A. (2000) · JAMA · doi:10.1001/jama.283.3.373 · Cited by 1,415
The Prescription Opioid and Heroin Crisis: A Public Health Approach to an Epidemic of Addiction
Kolodny, A., Courtwright, D. T., Hwang, C. S., Kreiner, P., Eadie, J. L., Clark, T. W., & Alexander, G. C. (2015) · Annual Review of Public Health · doi:10.1146/annurev-publhealth-031914-122957 · Cited by 1,388
U.S. Government Accountability Office
(2013) · Choice Reviews Online · doi:10.5860/choice.50-5961 · Cited by 997
New Technology and Health Care Costs — The Case of Robot-Assisted Surgery
Barbash, G. I., & Glied, S. A. (2010) · New England Journal of Medicine · doi:10.1056/nejmp1006602 · Cited by 993
The Promotion and Marketing of OxyContin: Commercial Triumph, Public Health Tragedy
Van Zee, A. (2009) · American Journal of Public Health · doi:10.2105/ajph.2007.131714 · Cited by 910
Kravitz, R. L., Epstein, R. M., Feldman, M. D., Franz, C. E., Azari, R., Wilkes, M. S., Hinton, L., & Franks, P. (2005) · JAMA · doi:10.1001/jama.293.16.1995 · Cited by 586
Scientific versus commercial sources of influence on the prescribing behavior of physicians
Avorn, J., Chen, M., & Hartley, R. (1982) · The American Journal of Medicine · doi:10.1016/0002-9343(82)90911-1 · Cited by 559
Spurling, G. K., Mansfield, P. R., Montgomery, B. D., Lexchin, J., Doust, J., Othman, N., & Vitry, A. I. (2010) · PLoS Medicine · doi:10.1371/journal.pmed.1000352 · Cited by 526
Gagnon, M.-A., & Lexchin, J. (2008) · PLoS Medicine · doi:10.1371/journal.pmed.0050001 · Cited by 502
A brief history of the opioid epidemic and strategies for pain medicine
Jones, M. R., Viswanath, O., Peck, J., Kaye, A. D., Gill, J. S., & Simopoulos, T. T. (2018) · Pain and Therapy · doi:10.1007/s40122-018-0097-6 · Cited by 405
A randomized trial of a program to reduce the use of psychoactive drugs in nursing homes
Avorn, J., Soumerai, S. B., Everitt, D. E., Ross-Degnan, D., Beers, M. H., Sherman, D., Salem-Schatz, S. R., & Fields, D. (1992) · New England Journal of Medicine · doi:10.1056/nejm199207163270306 · Cited by 397
Selling Stem Cells in the USA: Assessing the Direct-to-Consumer Industry
Turner, L., & Knoepfler, P. (2016) · Cell Stem Cell · doi:10.1016/j.stem.2016.06.007 · Cited by 384
Benefits and harms of direct to consumer advertising: a systematic review
Gilbody, S. (2005) · Quality and Safety in Health Care · doi:10.1136/qshc.2004.012781 · Cited by 222
Yeh, J. S., Franklin, J. M., Avorn, J., Landon, J., & Kesselheim, A. S. (2016) · JAMA Internal Medicine · doi:10.1001/jamainternmed.2016.1709 · Cited by 218
Brax, H., Fadlallah, R., Alkhaled, L., Kahale, L. A., Nas, H., El‐Jardali, F., & Akl, E. A. (2017) · PLoS ONE · doi:10.1371/journal.pone.0175493 · Cited by 190
Key opinion leaders: independent experts or drug representatives in disguise?
Moynihan, R. (2008) · BMJ · doi:10.1136/bmj.39575.675787.651 · Cited by 181
Moynihan, R. N., Cooke, G., Doust, J. A., Bero, L. A., Hill, S. R., & Glasziou, P. (2013) · PLoS Medicine · doi:10.1371/journal.pmed.1001500 · Cited by 178
Vassy, J. L., Christensen, K. D., Schonman, E. F., Blout, C. L., Robinson, J. O., Krier, J. B., Diamond, P. M., Lebo, M., Machini, K., Azzariti, D. R., et al. (2017) · Annals of Internal Medicine · doi:10.7326/m17-0188 · Cited by 167
Frosch, D. L., Grande, D., Tarn, D. M., & Kravitz, R. L. (2010) · American Journal of Public Health · doi:10.2105/ajph.2008.153767 · Cited by 162
Effects of Pharmaceutical Promotion on Adherence to the Treatment Guidelines for Depression
Donohue, J. M., Berndt, E. R., Rosenthal, M. B., Epstein, A. M., & Frank, R. G. (2004) · Medical Care · doi:10.1097/00005650-200412000-00004 · Cited by 161
Conflicts of Interest for Patient-Advocacy Organizations
McCoy, M. S., Carniol, M., Chockley, K., Urwin, J. W., Emanuel, E. J., & Schmidt, H. (2017) · New England Journal of Medicine · doi:10.1056/nejmsr1610625 · Cited by 160
King, M. D., Essick, C. J., Bearman, P., & Ross, J. S. (2013) · BMJ · doi:10.1136/bmj.f264 · Cited by 139
Hadland, S. E., Cerdá, M., Li, Y., Krieger, M. S., & Marshall, B. D. L. (2018) · JAMA Internal Medicine · doi:10.1001/jamainternmed.2018.1999 · Cited by 137
Internet-Based Direct-to-Consumer Genetic Testing: A Systematic Review
Covolo, L., Rubinelli, S., Ceretti, E., & Gelatti, U. (2015) · Journal of Medical Internet Research · doi:10.2196/jmir.4378 · Cited by 132
Guidance for Modifying the Definition of Diseases: A Checklist
Doust, J. A., Vandvik, P. O., Qaseem, A., Mustafa, R. A., Horvath, A. R., FRANCES, A. J., Al‐Ansary, L. A., Bossuyt, P. M., Ward, R. L., Kopp, I., et al. (2017) · JAMA Internal Medicine · doi:10.1001/jamainternmed.2017.1302 · Cited by 130
Layton, J. B., Kim, Y., Alexander, G. C., & Emery, S. (2017) · JAMA · doi:10.1001/jama.2016.21041 · Cited by 118
The Drug Facts Box: Improving the communication of prescription drug information
Schwartz, L. M., & Woloshin, S. (2013) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1214646110 · Cited by 103
Self-citationDatta, A., & Dave, D. (2016) · Health Economics · doi:10.1002/hec.3323 · Cited by 96
van der Wouden, C. H., Carere, D. A., Maitland-van der Zee, A. H., Ruffin, M. T., Roberts, J. S., Green, R. C., & for the Impact of Personal Genomics Study Group†* (2016) · Annals of Internal Medicine · doi:10.7326/m15-0995 · Cited by 95
Pharmaceutical Marketing and the New Social Media
Greene, J. A., & Kesselheim, A. S. (2010) · New England Journal of Medicine · doi:10.1056/nejmp1004986 · Cited by 93
Promotion of Prescription Drugs to Consumers and Providers, 2001–2010
Kornfield, R., Donohue, J. M., Berndt, E. R., & Alexander, G. C. (2013) · PLoS ONE · doi:10.1371/journal.pone.0055504 · Cited by 87
Mintzes, B. J. (2012) · Annual Review of Public Health · doi:10.1146/annurev-publhealth-031811-124540 · Cited by 83
King, M. D., & Bearman, P. (2016) · Social Science & Medicine · doi:10.1016/j.socscimed.2016.11.010 · Cited by 75
McKinlay, J. B., Trachtenberg, F. L., Marceau, L. D., Katz, J. N., & Fischer, M. A. (2014) · Medical Care · doi:10.1097/mlr.0000000000000096 · Cited by 68
What Are Cancer Centers Advertising to the Public? A Content Analysis
Vater, L. B., Donohue, J. M., Arnold, R. M., White, D. B., Chu, E., & Schenker, Y. (2014) · Annals of Internal Medicine · doi:10.7326/m14-0500 · Cited by 67
An Updated Analysis of Direct-to-Consumer Television Advertisements for Prescription Drugs
Applequist, J., & Ball, J. G. (2018) · The Annals of Family Medicine · doi:10.1370/afm.2220 · Cited by 64
Medicines Information and the Regulation of the Promotion of Pharmaceuticals
Alves, T. L., Lexchin, J., & Mintzes, B. J. (2018) · Science and Engineering Ethics · doi:10.1007/s11948-018-0041-5 · Cited by 63
Schwartz, L. M., & Woloshin, S. (2013) · JAMA Internal Medicine · doi:10.1001/jamainternmed.2013.7579 · Cited by 62
Self-citationUS drug marketing: how does promotion correspond with health value?
Greenway, T., & Ross, J. S. (2017) · BMJ · doi:10.1136/bmj.j1855 · Cited by 53
Personal Genomic Testing for Cancer Risk: Results From the Impact of Personal Genomics Study
Gray, S. W., Gollust, S. E., Carere, D. A., Chen, C. A., Cronin, A. M., Kalia, S. S., Rana, H. Q., Ruffin, M. T., Wang, C., Roberts, J. S., et al. (2017) · Journal of Clinical Oncology · doi:10.1200/jco.2016.67.1503 · Cited by 43
Presenting efficacy information in direct-to-consumer prescription drug advertisements
O’Donoghue, A. C., Sullivan, H. W., Aikin, K. J., Chowdhury, D., Moultrie, R., & Rupert, D. J. (2013) · Patient Education and Counseling · doi:10.1016/j.pec.2013.12.010 · Cited by 36
Evaluating the evidence: direct-to-consumer screening tests advertised online
Lovett, K. M., Mackey, T. K., & Liang, B. A. (2012) · Journal of Medical Screening · doi:10.1258/jms.2012.012025 · Cited by 31
Sullivan, H. W., Aikin, K. J., & Poehlman, J. A. (2017) · Health Communication · doi:10.1080/10410236.2017.1399509 · Cited by 27
Physicians, Industry Payments for Food and Beverages, and Drug Prescribing
Steinbrook, R. (2017) · JAMA · doi:10.1001/jama.2017.2477 · Cited by 26
Copay Assistance for Expensive Drugs: A Helping Hand That Raises Costs
Ubel, P. A., & Bach, P. B. (2016) · Annals of Internal Medicine · doi:10.7326/m16-1334 · Cited by 23
Addressing the Opioid Epidemic — Opportunities in the Postmarketing Setting
Psaty, B. M., & Merrill, J. O. (2017) · New England Journal of Medicine · doi:10.1056/nejmp1614972 · Cited by 23
Skeldon, S., Kozhimannil, K. B., Majumdar, S. R., & Law, M. R. (2014) · Journal of General Internal Medicine · doi:10.1007/s11606-014-3063-y · Cited by 21
Are Disease Awareness Links on Prescription Drug Websites Misleading? A Randomized Study
Sullivan, H. W., O’Donoghue, A. C., Rupert, D. J., Willoughby, J. F., Amoozegar, J. B., & Aikin, K. J. (2016) · Journal of Health Communication · doi:10.1080/10810730.2016.1237594 · Cited by 14
Salas, M., Martin, M. Y., Pisu, M., McCall, E., Zuluaga, A., & Glasser, S. P. (2008) · Pharmaceutical Medicine · doi:10.1007/bf03256691 · Cited by 13
Accuracy of Marketing Claims by Providers of Stereotactic Radiation Therapy
Narang, A. K., Lam, E., Makary, M. A., DeWeese, T. L., Pawlik, T. M., Pronovost, P. J., & Herman, J. M. (2013) · Journal of Oncology Practice · doi:10.1200/jop.2012.000693 · Cited by 13
Disease Information in Direct-to-Consumer Prescription Drug Print Ads
Aikin, K. J., Sullivan, H. W., & Betts, K. R. (2015) · Journal of Health Communication · doi:10.1080/10810730.2015.1058440 · Cited by 13
The Need for Vigilance in the Marketing of Genomic Tests in Psychiatry
Klitzman, R. (2015) · The Journal of Nervous and Mental Disease · doi:10.1097/nmd.0000000000000372 · Cited by 4
Cited by
Humphreys, K., Shover, C. L., Andrews, C. M., Bohnert, A. S. B., Brandeau, M. L., Caulkins, J. P., Chen, J. H., Cuéllar, M.-F., Hurd, Y. L., Juurlink, D. N., et al. (2022) · The Lancet · doi:10.1016/s0140-6736(21)02252-2 · Cited by 421
Mitchell, A. P., Trivedi, N. U., Gennarelli, R. L., Chimonas, S., Tabatabai, S. M., Goldberg, J., Diaz, L. A., & Korenstein, D. (2021) · Annals of Internal Medicine · doi:10.7326/m20-5665 · Cited by 262
Gottlieb, J. F., Benedetti, F., Geoffroy, P. A., Henriksen, T. E. G., Lam, R. W., Murray, G., Phelps, J., Sit, D., Swartz, H. A., Crowe, M., et al. (2019) · Bipolar Disorders · doi:10.1111/bdi.12847 · Cited by 196
Emerging technologies and analytics for a new era of value-centered marketing in healthcare
Agarwal, R., Dugas, M., Gao, G. (., & Kannan, P. K. (2020) · Journal of the Academy of Marketing Science · doi:10.1007/s11747-019-00692-4 · Cited by 175
“In the traditional volume-based system, marketing activities are focused on increasing sales and are directed toward health professionals rather than consumers (Schwartz and Woloshin 2019).”
BackgroundChervenak, J., Lieman, H., Blanco-Breindel, M., & Jindal, S. (2023) · Fertility and Sterility · doi:10.1016/j.fertnstert.2023.05.151 · Cited by 87
Metadata
- Authors
- Schwartz, L. M., & Woloshin, S.
- Venue
- JAMA
- Publisher
- American Medical Association (AMA)
- Published
- 2019-01-01
- Volume
- 321
- Issue
- 1
- Pages
- 80
- ISSN
- 0002-9955 (ISSN-L)
- 0098-7484
- OpenAlex
- W2909660049
- Cited by
- 379
- References
- 53
- FWCI
- 44.78
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.